[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368356-105":59,"doc-detail-368356-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-drug-bortezomib-triggers-cytotoxicity-in-microvascular-endothelial-cells-via-multi-organelle-stress","Cancer Drug Bortezomib - Triggers Cytotoxicity in Microvascular Endothelial Cells via Multi-Organelle Stress","","Proteasomes maintain cellular homeostasis by degrading abnormal proteins, while cancer cells exploit this system for survival and therapy. Bortezomib (BTZ) is a reversible proteasomal inhibitor used in multiple myeloma, mantle cell lymphoma, and non-small cell lung cancer, yet its toxicity mechanisms are incompletely understood. Here, BTZ and the irreversible inhibitor carfilzomib (CFZ) are compared in human pulmonary microvascular endothelial cells, showing BTZ-driven ER stress, mitochondrial dysfunction, ROS accumulation, and caspase activation within fifteen hours, followed by CASP8 cleavage, CASP3 activation, cell death, and vascular barrier loss by twenty-four hours. A pan-caspase inhibitor rescues BTZ cytotoxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-drug-bortezomib-triggers-cytotoxicity-in-microvascular-endothelial-cells-via-multi-organelle-stress/368356/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-drug-bortezomib-triggers-cytotoxicity-in-microvascular-endothelial-cells-via-multi-organelle-stress/368356.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main finding about bortezomib versus carfilzomib in endothelial cells?","Question",{"text":112,"@type":113},"Bortezomib (BTZ) is cytotoxic to non-cancerous microvascular endothelial cells, while carfilzomib (CFZ) does not elicit the same ER stress and downstream cascade described. The endothelial response includes mitochondrial compromise, ROS accumulation, and caspase activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which cellular stress pathways are implicated after bortezomib treatment?",{"text":117,"@type":113},"BTZ triggers endoplasmic reticulum (ER) stress and mitochondrial stress. The work links ER stress to the IRE1α-CHOP pathway and connects mitochondrial stress to reactive oxygen species (ROS) accumulation and caspase activation.",{"name":119,"@type":110,"acceptedAnswer":120},"How does caspase inhibition affect bortezomib-induced cytotoxicity?",{"text":121,"@type":113},"A pan-caspase inhibitor (zVAD) significantly rescues BTZ-treated cells from cytotoxicity, indicating that caspase signaling is required for the lethal effects observed.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368356,1790472723,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","bioRxiv preprint doi: [https://doi.org/10.1101/2025.03.25.645304](https://doi.org/10.1101/2025.03.25.645304); this version posted March 26, 2025. The copyright holder has placed this preprint (which was not certified by peer review) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors.  \n1 Cancer Drug Bortezomib, a Proteasomal Inhibitor, Triggers Cytotoxicity in  \n2 Microvascular Endothelial Cells via Multi-Organelle Stress  \n3  \n4 Authors: Prajakta Sawant 1,2, Aleena Mathew2, Johanna Bensalel 1,2, Julio Gallego-  \n5 Delgado 1,2,3, Pratyusha Mandal 1,2,3* 6  \n7 Affiliations:  \n8 1Doctoral Program in Biology (Molecular, Cellular & Developmental Biology), The Graduate  \n9 Center, The City University of New York, New York, NY 10016, USA  \n10 2Department of Biological Sciences, Bronx, Lehman College, The City University of New  \n11 York,  \n12 New York, NY 10468, USA  \n13 3Doctoral Program in Biochemistry, The Graduate Center, The City University of New York,  \n14 New York, NY 10016, USA 15  \n16 *[Corresponding author. pratyusha.mandal@lehman.cuny.edu](Corresponding author. pratyusha.mandal@lehman.cuny.edu).  \n17 Requests for materials should be sent to this [author:](author: pratyusha.mandal@lehman.cuny.edu)[ ](author: pratyusha.mandal@lehman.cuny.edu)[pratyusha.mandal@lehman.cuny.edu](author: pratyusha.mandal@lehman.cuny.edu)  \n18 Dept of Biological Sciences, Lehman College,  \n19 Biology and Biochemistry Programs,  \n20 The Graduate Center, CUNY.  \n21 250 Bedford Park Blvd, The Bronx,  \n22 NY 10468.  \n23 Phn: Office 718 960 8644  \n24 Cell:937 869 3978  \nbioRxiv preprint doi: [https://doi.org/10.1101/2025.03.25.645304](https://doi.org/10.1101/2025.03.25.645304); this version posted March 26, 2025. The copyright holder has placed this preprint (which was not certified by peer review) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors.  \n25 Abstract  \n26 Proteasomes maintain cellular homeostasis by degrading abnormal proteins, while cancer  \n27 cells exploit them for survival, becoming a key chemotherapeutic target. Bortezomib (BTZ), 28 a reversible proteasomal inhibitor, is a front-line treatment for multiple myeloma, mantle cell  \n29 lymphoma, and non-small cell lung cancer. However, its efficacy is limited by severe side  \n30 effects, including neurotoxicity and cardiovascular distress, with its toxicity mechanisms  \n31 largely unexplored. Here, we discover that Bortezomib (BTZ), is cytotoxic to non-cancerous  \n32 cells distinctly from Carfilzomib (CFZ), the second-line irreversible PI. BTZ or CFZ is  \n33 administered intravenously, impacting blood vessel (vascular) endothelial cells. We used  \n34 human pulmonary microvascular endothelial cells (HPMECs) to demonstrate that BTZ but  \n35 not CFZ elicits endoplasmic reticulum (ER) stress, mitochondrial membrane compromise, 36 mitochondrial reactive oxygen species (ROS) accumulation, and Caspase (CASP)9 activation  \n37 (mediator of Intrinsic apoptosis) within fifteen hours of treatment. By twenty-four hours, 38 BTZ-treated cells display cleavage of CASP8 (mediator of extrinsic apoptosis), activation of  \n39 CASP3 (terminal executioner of apoptosis), cell-death and vascular barrier loss. Pan-caspase  \n40 inhibitor zVAD significantly rescues BTZ-treated cells from cytotoxicity. Both BTZ and CFZ  \n41 effectively kill MM cells. These findings reveal novel insights into fundamental signaling of  \n42 regular cells where reversible inhibition of the proteasome dictates a unique cascade of stress  \n43 distinct from irreversible inhibition. These harmful effects of BTZ emphasize the need to re- 44 evaluate its use as a frontline chemotherapy for MM.  \n45 Keywords: Bortezomib, Velcade, Carfilzomib, Krypsolis, Proteasomal Inhibitors, Apoptosi","cbCaijmLNC0AU6Bq","https://ap.wps.com/l/cbCaijmLNC0AU6Bq","pdf",1649681,43,"English","# Abstract\n# Highlights\n# Introduction","[{\"question\":\"What is the main finding about bortezomib versus carfilzomib in endothelial cells?\",\"answer\":\"Bortezomib (BTZ) is cytotoxic to non-cancerous microvascular endothelial cells, while carfilzomib (CFZ) does not elicit the same ER stress and downstream cascade described. The endothelial response includes mitochondrial compromise, ROS accumulation, and caspase activation.\"},{\"question\":\"Which cellular stress pathways are implicated after bortezomib treatment?\",\"answer\":\"BTZ triggers endoplasmic reticulum (ER) stress and mitochondrial stress. The work links ER stress to the IRE1α-CHOP pathway and connects mitochondrial stress to reactive oxygen species (ROS) accumulation and caspase activation.\"},{\"question\":\"How does caspase inhibition affect bortezomib-induced cytotoxicity?\",\"answer\":\"A pan-caspase inhibitor (zVAD) significantly rescues BTZ-treated cells from cytotoxicity, indicating that caspase signaling is required for the lethal effects observed.\"}]","Cancer Drug Bortezomib - Triggers Cytotoxicity in Microvascular Endothelial Cells via Multi-Organelle Stress | PDF",1790176512,108,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/642580513bed3367240fdd8f09e4c74c.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d788c6087f9a0c946541cc8d4c35d38d.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/577460a14ce51049c984078766d8757f.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dba897fbc5bd117910174dca20ca11e.webp",980,1268,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0a5928b59b1d81c29a7cf9e0064fc38.webp",979,1267]